Details of the Target
General Information of Target
Target ID | LDTP02536 | |||||
---|---|---|---|---|---|---|
Target Name | Leukocyte antigen CD37 (CD37) | |||||
Gene Name | CD37 | |||||
Gene ID | 951 | |||||
Synonyms |
TSPAN26; Leukocyte antigen CD37; Tetraspanin-26; Tspan-26; CD antigen CD37 |
|||||
3D Structure | ||||||
Sequence |
MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV
LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLR DVVEKTIQKYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAHRVPCS CYNLSATNDSTILDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGLQKWLHN NLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR |
|||||
Target Type |
Clinical trial
|
|||||
Target Bioclass |
Other
|
|||||
Family |
Tetraspanin (TM4SF) family
|
|||||
Subcellular location |
Membrane
|
|||||
TTD ID | ||||||
Uniprot ID | ||||||
DrugMap ID | ||||||
Ensemble ID | ||||||
HGNC ID | ||||||
ChEMBL ID |
Target Site Mutations in Different Cell Lines
Probe(s) Labeling This Target
ABPP Probe
Probe name | Structure | Binding Site(Ratio) | Interaction ID | Ref | |
---|---|---|---|---|---|
DBIA Probe Info |
![]() |
C217(1.53) | LDD3372 | [1] | |
IA-alkyne Probe Info |
![]() |
N.A. | LDD0166 | [2] |
Competitor(s) Related to This Target
Competitor ID | Name | Cell line | Binding Site(Ratio) | Interaction ID | Ref |
---|---|---|---|---|---|
LDCM0625 | F8 | Ramos | C230(1.20); C217(4.34) | LDD2187 | [3] |
LDCM0573 | Fragment11 | Ramos | C230(0.62) | LDD2190 | [3] |
LDCM0575 | Fragment13 | Ramos | C230(1.29); C217(0.74) | LDD2192 | [3] |
LDCM0576 | Fragment14 | Ramos | C217(1.22) | LDD2193 | [3] |
LDCM0580 | Fragment21 | Ramos | C230(1.46); C217(0.50) | LDD2195 | [3] |
LDCM0582 | Fragment23 | Ramos | C230(0.88) | LDD2196 | [3] |
LDCM0578 | Fragment27 | Ramos | C230(1.15) | LDD2197 | [3] |
LDCM0586 | Fragment28 | Ramos | C230(1.09); C217(0.74) | LDD2198 | [3] |
LDCM0588 | Fragment30 | Ramos | C230(1.91); C217(1.33) | LDD2199 | [3] |
LDCM0589 | Fragment31 | Ramos | C230(1.48); C217(1.39) | LDD2200 | [3] |
LDCM0468 | Fragment33 | Ramos | C230(3.34); C217(1.03) | LDD2202 | [3] |
LDCM0596 | Fragment38 | Ramos | C230(3.00); C217(4.24) | LDD2203 | [3] |
LDCM0566 | Fragment4 | Ramos | C217(1.90) | LDD2184 | [3] |
LDCM0610 | Fragment52 | Ramos | C230(2.44) | LDD2204 | [3] |
LDCM0614 | Fragment56 | Ramos | C230(1.86); C217(1.07) | LDD2205 | [3] |
LDCM0569 | Fragment7 | Ramos | C230(3.12); C217(1.03) | LDD2186 | [3] |
LDCM0022 | KB02 | Ramos | C217(1.94) | LDD2182 | [3] |
LDCM0023 | KB03 | Ramos | C217(1.30) | LDD2183 | [3] |
LDCM0024 | KB05 | OCI-Ly3 | C217(1.53) | LDD3372 | [1] |
The Interaction Atlas With This Target
The Protein(s) Related To This Target
Enzyme
Transporter and channel
Other
Protein name | Family | Uniprot ID | |||
---|---|---|---|---|---|
Leucine-rich repeat-containing protein 3B (LRRC3B) | LRRC3 family | Q96PB8 | |||
Epithelial membrane protein 1 (EMP1) | PMP-22/EMP/MP20 family | P54849 |
The Drug(s) Related To This Target
Phase 2
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Bi-836826 | Antibody | D09WKM | |||
Gen3009 | Antibody | D1W2DS | |||
Imgn529 | Antibody | D0C0LO | |||
Naratuximab Emtansine | Antibody | D2R0UM | |||
Otlertuzumab | . | D08JGB | |||
Tru-016 | . | D0T7QC |
Preclinical
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
212pb-labelled Acd37 | Radiopharmaceutical therapy | DI9ZQ6 |
References